TAK vs. WAT: Takeda Pharmaceutical vs. Waters Stock Comparison

Company Profile

Takeda Pharmaceutical (TAK) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TAK is classified in Pharmaceuticals while WAT is classified in Life Sciences Tools & Services.

Waters (WAT) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Waters (WAT) has a non-negative beta of 1.13.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Takeda Pharmaceutical (TAK) at 0.56% and Waters (WAT) at 1.12% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Takeda Pharmaceutical (TAK) at 0.87% and Waters (WAT) at 1.76% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Takeda Pharmaceutical (TAK) at 24.55% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.

Profitability Metrics

Growth

Waters (WAT) at 6.99% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Waters (WAT) at 0.47% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Takeda Pharmaceutical (TAK) shows current ratio of 1.15 against its industry benchmark, while Waters (WAT) has no reading this period.

Waters (WAT) at 0.34 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Waters (WAT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Waters (WAT) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Takeda Pharmaceutical (TAK) at 300.29 and Waters (WAT) at 191.46 trade above their industries’ P/E ratio peer ranges, pointing to unusually expensive trailing earnings relative to peers.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Waters (WAT) at 8.01 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Waters (WAT) at 2.94 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics